Thais Martins-Gonçalves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thais Martins-Gonçalves has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Herrison Fontana
Department of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil
3 shared publications - Johana Becerra
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
3 shared publications - Nilton Lincopan
Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil
3 shared publications - Bruna Fuga
Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília, Brazil
2 shared publications - Fernanda Borges Barbosa
Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, Sao Paulo, Brazil
2 shared publications - Fábio Parra Sellera
School of Veterinary Medicine, Metropolitan University of Santos, Santos, Brazil
2 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 73
Illegally trafficked exotic snake as a reservoir for the novel carbapenem-resistant and hypervirulent Pseudomonas aeruginosa ST4309
- 25 August 2026
- Published by Elsevier in New Microbes and New Infections
- Vol. 73
Open AccessIllegally trafficked exotic snake as a reservoir for the novel carbapenem-resistant and hypervirulent Pseudomonas aeruginosa ST4309
- Open Access
- 30 July 2026
- Published by Elsevier in Veterinary and Animal Science
- Vol. 33, 100793
Multidrug-resistant avian pathogenic Escherichia coli ST162 among trafficked psittacine birds
- 30 July 2026
- Published by Elsevier in Veterinary and Animal Science
- Vol. 33, 100793
Open AccessMultidrug-resistant avian pathogenic Escherichia coli ST162 among trafficked psittacine birds
- Open Access
- 15 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 262-264
Salmonella Minnesota sequence type 548 harbouring a type 2 IncC megaplasmid of antimicrobial resistance and virulence (pESM) infecting a companion animal
- 15 July 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 262-264
Open AccessSalmonella Minnesota sequence type 548 harbouring a type 2 IncC megaplasmid of antimicrobial resistance and virulence (pESM) infecting a companion animal
- Open Access
- 5 February 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (4) , 101071
Tracking pandemic pathogens from wastewater surveillance in international airports: Klebsiella pneumoniae ST16 coproducing NDM-4 and OXA-181 arriving in South America
- 5 February 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (4) , 101071
Open AccessTracking pandemic pathogens from wastewater surveillance in international airports: Klebsiella pneumoniae ST16 coproducing NDM-4 and OXA-181 arriving in South America
- 28 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 162-168
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain susceptible to meropenem, suggesting a potential therapeutic use of this antibiotic. In this study, the efficacy of clinically relevant concentrations of meropenem was evaluated against high-risk clones of ceftazidime–avibactam-resistant K. pneumoniae strains producing KPC variants, in a tandem in vitro time-kill/in vivo Galleria mellonella survival model. In vitro/in vivo efficacy of meropenem against ceftazidime–avibactam-resistant K. pneumoniae of CG16, CG25 and CG258, producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114 variants, was evaluated using EUCAST dosing recommendation adjusted to the G. mellonella model. For in vivo assays, untreated, meropenem (40 mg/kg × 1)-treated and ceftazidime–avibactam (40 mg/kg ceftazidime–10 mg/kg avibactam × 1)-treated groups were established, with 60 larvae per group. Kaplan–Meier curves, log-rank tests, univariate Cox regression and hazard ratios (HR) were used to assess treatment effects (P < 0.05). For all KPC-variant producers, time-kill assays showed >3 log-kills reduction (−6.91 ± 1.28 SD) after 6 h interaction when exposed to 8–32 mg/L meropenem MIC values (i.e. ≥ × 4 MIC). In the assessment of in vivo efficacy of meropenem, at the 4-day follow-up, mortality rates were 96.7% (untreated), 83.3% (ceftazidime–avibactam-treated) and 13.3% (meropenem-treated) (P < 0.05). Univariate Cox regression analysis showed significantly lower risk in the meropenem group compared to untreated group [HR 0.02 (95% CI: 0.01–0.05)]. These pre-clinical results might support use of meropenem as a potential alternative for treatment of infections due to KPC-variant producers displaying in vitro susceptibility to meropenem.
- 28 October 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 162-168
Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114
Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain susceptible to meropenem, suggesting a potential therapeutic use of this antibiotic. In this study, the efficacy of clinically relevant concentrations of meropenem was evaluated against high-risk clones of ceftazidime–avibactam-resistant K. pneumoniae strains producing KPC variants, in a tandem in vitro time-kill/in vivo Galleria mellonella survival model. In vitro/in vivo efficacy of meropenem against ceftazidime–avibactam-resistant K. pneumoniae of CG16, CG25 and CG258, producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114 variants, was evaluated using EUCAST dosing recommendation adjusted to the G. mellonella model. For in vivo assays, untreated, meropenem (40 mg/kg × 1)-treated and ceftazidime–avibactam (40 mg/kg ceftazidime–10 mg/kg avibactam × 1)-treated groups were established, with 60 larvae per group. Kaplan–Meier curves, log-rank tests, univariate Cox regression and hazard ratios (HR) were used to assess treatment effects (P < 0.05). For all KPC-variant producers, time-kill assays showed >3 log-kills reduction (−6.91 ± 1.28 SD) after 6 h interaction when exposed to 8–32 mg/L meropenem MIC values (i.e. ≥ × 4 MIC). In the assessment of in vivo efficacy of meropenem, at the 4-day follow-up, mortality rates were 96.7% (untreated), 83.3% (ceftazidime–avibactam-treated) and 13.3% (meropenem-treated) (P < 0.05). Univariate Cox regression analysis showed significantly lower risk in the meropenem group compared to untreated group [HR 0.02 (95% CI: 0.01–0.05)]. These pre-clinical results might support use of meropenem as a potential alternative for treatment of infections due to KPC-variant producers displaying in vitro susceptibility to meropenem.